CubeBio Heads to a Vote With $862,000 Left in the SPAC Trust
The Korean cancer-screening developer seeks a $375 million public-market valuation despite no product revenue, limited cash and no minimum-cash condition.
SEOUL, October 2, 2026 • CubeBio is asking public investors to look past a nearly empty SPAC trust and underwrite the commercial promise of urine-based cancer screening. Mountain Crest Acquisition Corp. V has set an October 29 shareholder vote on the combination, which would bring the Korean diagnostics developer to the public market as CubeBio Holdings Ltd under the proposed Nasdaq symbol KUBE.
The vote date is the immediate catalyst. The financing available at closing is the harder question. Mountain Crest had approximately $861,864 in its trust as of September 14, equal to an estimated $11.95 for each of the roughly 72,000 remaining public shares, according to the final proxy statement and prospectus. Public holders have until 5 p.m. Eastern on October 27 to request redemption.
There is no minimum-cash condition. Whatever remains after redemptions can support working capital, but this is no longer a meaningful SPAC cash infusion. IPOGrid reads the transaction primarily as a listing event and ownership exchange, with any usable growth capital still to be raised.
A $375 million valuation meets a pre-revenue business
The deal calls for CubeBio shareholders to receive 37.5 million shares, implying $375 million at the agreement's $10 reference price. Existing CubeBio holders would command about 90% of the company at closing, while Mountain Crest's public shareholders would own roughly 1.8% before any further redemptions. The prospectus registers 42.15 million ordinary shares, but those are principally merger consideration and other transaction shares, not a new underwritten sale generating $421.5 million for the company.
That distinction matters because CubeBio remains pre-revenue. The company generated no revenue in either 2024 or 2025 because it had no products approved for sale. It lost ₩6.14 billion, or about $4.25 million, in 2025 after losing ₩8.07 billion in 2024. At June 30, 2026, it held only ₩342 million, or about $237,000, of cash and cash equivalents. The filing says these conditions raise substantial doubt about its ability to continue as a going concern.
CubeBio's products are built around urine samples and specific metabolite concentrations, with candidates aimed at screening for pancreatic and several other cancers. The company describes encouraging clinical performance for its pancreatic-cancer candidate, but the investable issue is regulatory and commercial execution. CubeBio itself says it does not expect product revenue in the near future and that sales depend on approvals and eventual commercialization.
Distribution agreements provide a route to market, though not current demand in the public-equity sense. When the definitive merger agreement was announced in 2024, the parties highlighted a roughly $14.5 million Taiwan Biotech distribution contract covering Taiwan, Vietnam and Malaysia, while warning that revenue would not begin until approvals were obtained and could take 24 months or longer, according to the transaction announcement. The final prospectus now says regulatory submissions and staged commercialization are assumed to begin in 2027.
The vote looks easier than the financing
The sponsor and other initial stockholders hold approximately 70.5% of Mountain Crest's outstanding shares and have agreed to vote for the proposals. That gives the transaction a clear path through the meeting if procedural conditions are met. It does not answer how CubeBio funds product development, approvals and commercialization after closing.
The incentives are unusually visible. The prospectus estimates the sponsor would lose approximately $27.75 million if Mountain Crest fails to complete a business combination, including the stated market value of founder shares and private units plus an interest-free loan. The reviewer's concern is that this exposure rewards completion even when the trust contributes little cash. Public holders can redeem and still vote in favor, so approval should not be read as evidence of new capital commitment.
The original economics also contain a large earnout: 24.5 million additional shares become issuable if CubeBio reports at least $42.7 million of revenue for 2026. Against zero revenue in 2025 and management's statement that product revenue is not expected in the near future, our interpretation is that investors should value that earnout as contingent dilution rather than evidence of operating momentum.
Listing approval remains the final gate
Mountain Crest's common stock, rights and units are quoted on the OTC Pink market after Nasdaq suspended them. CubeBio intends to list the post-combination ordinary shares on Nasdaq as KUBE, but the prospectus says approval is not assured. That caveat carries more weight here because the SPAC's securities have already lost their Nasdaq venue.
CubeBio deserves attention today because the calendar is finally concrete after a transaction first announced in August 2024. The vote is set, the redemption deadline is visible and the registration statement is effective. The commercial case remains much earlier: no approved product, no revenue, a going-concern warning and very little closing cash. For KUBE, the listing may arrive before the financing solution.